The host range of the B-lymphotropic papovavirus (LPV) in cultured human cells is limited to a few B-lymphoma-derived cell lines. The constitutively expressed cell surface receptor for the virus is a major determinant restricting the LPV host range (G. Haun, 0. T. Keppler, C. T. Bock, M. Herrmann, H. Zentgraf, and M. Pawlita, J. Virol. 67:7482-7492, 1993 Attachment of virus particles to specific receptors on the plasma membrane is the initial event in the interaction of viruses with their host cells. The presence and functional state of such cellular receptors are one major determinant of the species and tissue tropism of many viruses. Examples are CD4 on T lymphocytes and macrophages for human immunodeficiency virus type 1 (2), the complement C3d receptor CR2 (CD21) on B lymphocytes for Epstein-Barr virus (EBV) (7), the intercellular adhesion molecule 1 (ICAM-1) for the major subgroup of rhinoviruses (10, 24, 26) , and aminopeptidase N (CD13) on pig small intestine epithelial cells for the transmissible gastroenteritis virus (3).
tunicamycin-induced LPV receptor. We conclude that removal or modification of certain N-linked oligosaccharides in human B-lymphoma cells can enhance expression or functional activity of the sialylated LPV receptor.
Attachment of virus particles to specific receptors on the plasma membrane is the initial event in the interaction of viruses with their host cells. The presence and functional state of such cellular receptors are one major determinant of the species and tissue tropism of many viruses. Examples are CD4 on T lymphocytes and macrophages for human immunodeficiency virus type 1 (2), the complement C3d receptor CR2 (CD21) on B lymphocytes for Epstein-Barr virus (EBV) (7) , the intercellular adhesion molecule 1 (ICAM-1) for the major subgroup of rhinoviruses (10, 24, 26) , and aminopeptidase N (CD13) on pig small intestine epithelial cells for the transmissible gastroenteritis virus (3) .
The host range of the African green monkey B-lymphotropic papovavirus (LPV), a primate polyomavirus with about equal sequence homology to simian virus 40 (SV40) and mouse polyomavirus (19) , is highly restricted in cultured human cells. Productive LPV infection could only be obtained in some Burkitt's lymphoma-derived cell lines and, very inefficiently, in a few EBV-immortalized human B-lymphoblastoid cells (21, 25, 28, 29) . The presence of a constitutively expressed LPV receptor function on the surface of several human hematopoietic cell lines correlates with susceptibility to infection, indicating that this cell surface receptor is at least a major determinant restricting the LPV host range (12) . Recently, we have isolated subclones of the human B-lymphoma line BJA-B which differ greatly in receptor expression and concomitantly in susceptibility to LPV infection (20) . The molecule(s) forming the receptor has not yet been identified. The trypsin and sialidase sensitivity of LPV binding and infection suggests the involvement of proteinaceous and sialylated components in the LPV receptor (12) .
Oligosaccharide chains on glycoproteins can play an important role in differentiation and cell recognition. They can be N linked to asparagine residues or 0 linked to serine and threonine residues. For example, many cells derived from the human hematopoietic system express leukosialin (CD43), a glycoprotein with many 0-linked oligosaccharides in which the specific structure of the oligosaccharides is thought to be characteristic for each cell lineage and maturation stage (9, 22) . In contrast to being a necessary component in several defined molecular functions, oligosaccharides may also inhibit function by masking sites required for receptor-ligand interactions or by altering the secondary structure of such sites. For example, the removal of terminal sialic acids from serum glycoproteins allows recognition of these asialoglycoproteins by a galactose-specific lectin on hepatocytes, leading to their cellular uptake and degradation (1) . Also, cleavage of certain influenza virus hemagglutinins can be inhibited by an oligosaccharide side chain located in the vicinity of the cleavage site between hemagglutinin 1 (HA1) and HA2 (13) . More recently, it has been shown that inhibition of N-linked glycosylation or point mutation of a single N glycosylation site -of an ecotropic murine leukemia virus receptor resulted in activation of the receptor function (4, 27 (20) .
Viruses. Stocks of LPV and SV40 were prepared from infected BJA-B and TC7 cells, respectively, as described previously (12) .
LPV binding and infection. LPV binding was determined by an indirect, nonradioactive virus-binding assay essentially as described previously (12) . Pretreated cells were washed, serially diluted in phosphate-buffered saline (PBS) containing 0.2% gelatine, and incubated in 96-well tissue culture plates in a final volume of 200 ,ul with a constant amount of LPV particles (corresponding to 800 pg of LPV VP1) for 30 min.
Analysis of binding kinetics had shown that under these conditions, equilibrium was reached. After low-speed sedimentation of cells (400 x g), the amount of unbound LPV VP1 in the supernatant was quantitated by enzyme-linked immunosorbent assay (ELISA) (12) .
To determine the susceptibility of cell lines to LPV infection, 106 cells were washed and resuspended in 1 ml of medium containing 200 ,ul of LPV stock virus (corresponding to about one infectious unit per cell). Cells were exposed to LPV at 37°C for 2 h, 2 ml of medium was added, and cells were cultured for 48 to 70 h. The number of LPV-infected cells was determined by indirect immunofluorescence microscopy staining for LPV T and VP antigens as described previously (12) . To determine the amount of viral antigen produced in infected cultures, cell pellets were extracted in a hypotonic lysis buffer and LPV VP1 antigen relative to total protein content in the extract was quantitated by ELISA (12, 14 (12) . To further characterize the oligosaccharide moiety of the receptor, experiments with glycosylation inhibitors were carried out.
The N glycosylation inhibitor tunicamycin blocks the first step in glycoprotein N glycosylation, i.e., the transfer of dolichol phosphate-linked oligosaccharides to the amido group of asparagine residues in the endoplasmic reticulum (5). BJA-B cells were pretreated with 1.2 ,iM tunicamycin for 48 h and exposed to LPV, and the degree of infection was quantitated 2 days postinfection, which allows only one viral replicative cycle. LPV (Fig.  1A) . The increased susceptibility was also reflected in the increased production of viral antigen. In uncloned parental BJA-B cells, virus production rose approximately fourfold from 300 to 1,300 ng of VP1 per mg of extracted protein (Fig.  1B) . In low-susceptibility subclones K138, K9, K6, and K20, LPV antigen production was enhanced 34-to 83-fold and reached the level of that in untreated parental BJA-B cells and high-susceptibility subclones K88 and K43. In these highsusceptibility subclones, tunicamycin pretreatment also enhanced LPV antigen production. A (Fig. 2b) .
Cell proliferation was significantly affected at higher tunicamycin concentrations (see Fig. 4b ), and, in addition, concentrations above 3 ,uM were cell toxic. A tunicamycin concentration of 1 (Fig. 3) . In control experiments, DEAE-dextran-mediated calculated as the ratio of VP1 produced in tunicamycin-treated cultures to VP1 produced in untreated cultures. oligosaccharides are further processed by sequential actions of glycosidases and glycosyltransferases first in the endoplasmic reticulum and then in the Golgi apparatus. In addition to tunicamycin, which inhibits the first step in N glycosylation, inhibitors with selective influences on N-linked oligosaccharide processing are available (reviewed in references 5 and 6). Castanospermine and dNoj both inhibit glucosidases of the endoplasmic reticulum, thus blocking the synthesis of hybrid and complex N-linked sugar chains and increasing high-mannose oligosaccharides. dManNoj inhibits mannosidase I in the Golgi complex and causes a decrease in complex types of oligosaccharides and an increase in high-mannose oligosaccharides. Swainsonine inhibits Golgi mannosidase II, resulting in the replacement of complex N oligosaccharide chains by hybrid chains.
These four glycosylation processing inhibitors were tested for their effect on LPV infection in low-susceptibility BJA-B K6 cells. Concentrations that had been shown to be effective in other cell systems were chosen (6). Treatment with dManNoj (0.4 mM) increased susceptibility to subsequent LPV infection 23-fold, whereas the three other processing inhibitors, dNoj, swainsonine, and castanospermine (4 mM, 20 ,uM, and 0.5 mM, respectively), had no apparent effect (Fig. 4a) . The enhancement of LPV susceptibility by dManNoj to approximately 200 ng of VP1 per mg of protein was not as pronounced as that seen with tunicamycin, with which a level of 3,000 ng of VP1 per mg of protein was reached (Fig. 2a) .
In contrast to tunicamycin, neither dManNoj nor any of the other three glycosylation processing inhibitors significantly affected viability or proliferation of cells during 48 h of treatment (Fig. 4b) . To test whether inhibition of cell proliferation in general might contribute to the strong tunicamycininduced enhancement of LPV susceptibility, K6 cells pretreated with another cell proliferation-inhibiting substance, the protein biosynthesis inhibitor cycloheximide, were infected with LPV. Cycloheximide at 0.4 ,uM reduced cell proliferation and viability to a similar extent as did tunicamycin at 1.2 ,uM but did not enhance LPV infection (Fig. 3) . These data provide evidence that the induction of LPV susceptibility by tunicamycin and dManNoj is caused by a specific effect on protein N glycosylation.
Other human B-lymphoma cell lines are also rendered susceptible to LPV infection by inhibition of N glycosylation. The possible enhancement of LPV susceptibility by N glycosylation inhibition was also tested with a series of other cell lines with no or low-level LPV susceptibility. All the lines used are capable of expressing and replicating transfected LPV DNA (20) . dManNoj was chosen since it can effectively induce LPV susceptibility without affecting cell proliferation. In all cell lines outside the B-lymphoid differentiation pathway, i.e., the promyelocytic leukemia line HL60, the chronic myelogenous leukemia line K562, and T-lymphoid leukemia lines Jurkat and MT-4, as well as the monkey kidney epithelium cell line Vero, dManNoj pretreatment could not induce LPV susceptibility more than twofold (Fig. 5) . In pretreated EBV-immortalized The enhancement of LPV susceptibility by N glycosylation inhibition is mediated by enhancement of LPV binding. Since LPV receptor expression had previously been shown to be a major determinant of LPV host range (12), we analyzed whether the enhancement of LPV susceptibility by tunicamycin could be due to enhanced LPV binding to host cells. Varying numbers of cells were incubated with a constant amount of LPV, virus binding was allowed to occur for 30 min, and after low-speed centrifugation, the amount of free LPV in the supernatant was quantitated by LPV VP1 ELISA. The cell numbers required to bind 50% of the administered virus were taken as the definition of the relative LPV-binding capacities of inhibitor-treated and untreated cells (Fig. 6) .
Untreated cells of the low-LPV-susceptibility BJA-B subclone K20 display a very low LPV-binding capacity, with 2 x 106 cells needed to bind 400 pg of LPV VP1 (Fig. 6b) The tunicamycin-induced LPV receptor on BJA-B cells is sialic acid dependent and possibly identical with the constitutively expressed LPV receptor. Sialic acid is an essential component of the constitutively expressed receptor (12, 14) . We therefore analyzed whether the tunicamyin-induced receptor also requires sialic acid to bind LPV. On BJA-B K20 cells with low-level constitutive LPV binding and susceptibility, the tunicamycin-induced LPV binding was reduced by 85% after enzymatic desialylation with V cholerae sialidase (Fig. 6b) . This enzyme also efficiently removes the functionally essential sialic acid from the constitutively expressed LPV receptor on untreated K88 cells (Fig. 6a) (12) . We have also shown previously that in susceptible BJA-B cells treated with sialidase, the amount of LPV receptor is reduced and limits the infection. The increase in binding and infection induced by tunicamycin pretreatment described here shows that, even in constitutively susceptible BJA-B cells, LPV receptor expression is the limiting factor for viral infection.
For the high-susceptibility BJA-B subclone K88, tunicamycin pretreatment enhanced virus binding fourfold and susceptibility sixfold, suggesting a positive correlation. However, in the low-susceptibility K20 cells, a 10-fold increase in virusbinding capacity was accompanied by an over 100-fold increase in the number of infected cells and an 83-fold increase in virus production, indicating a nonlinear relationship between virusbinding capacity and susceptibility. The overproportional increase in susceptibility in the low-binding-level cells after tunicamycin treatment could be explained by a model in which several virus-binding sites have to cooperate to form a site sufficient for virus uptake. Hence, in cell membranes in which the concentration of binding sites is higher, the formation of a functional uptake site would occur more efficiently, leading to an overproportional increase in infection.
Although the molecular natures of the constitutive LPV receptor and the tunicamycin-induced receptor are still unknown, some information on the oligosaccharide(s) necessary for virus binding and infection is available. Both receptors are sensitive to enzymatic desialylation by V cholerae sialidase. The sialic acid-containing oligosaccharide(s) on the tunicamycin-induced receptor is unlikely to be N linked. The high binding capacity of tunicamycin-treated K88 cells is best explained by an additive effect of constitutive and tunicamycininduced receptors on these cells, which suggests that the sialic acid on the constitutive receptor is also not N linked. This raises the possibility that the constitutive and the tunicamycininduced receptors are identical. This interpretation is further supported by the finding that tunicamycin induction of LPV susceptibility appears restricted to B-lymphoma-derived cell lines, i.e., the cell type to which almost all cells with known constitutive LPV susceptibility belong (21, 25, 28, 29) . It remains to be determined whether the sialic acid(s) necessary for receptor function is part of the 0-linked oligosaccharides on a glycoprotein or is located on membrane glycolipids. The former is favored by the trypsin sensitivity of the constitutive LPV receptor (12) .
Besides inhibiting the N glycosylation of nascent proteins in the endoplasmic reticulum, at the concentrations used here, tunicamycin might also affect protein synthesis, as has been described for several experimental systems (reviewed in reference 6). In our experiments, tunicamycin clearly had a potent on November 7, 2017 by guest http://jvi.asm.org/ Downloaded from effect on cell proliferation and cell viability. However, we conclude that with tunicamycin also, the effect is specifically due to inhibition of correct N glycosylation and not to inhibition of cell proliferation per se, since the N glycosylation processing inhibitor dManNoj displayed a similar effect on LPV susceptibility without inhibition of proliferation and since protein synthesis impairment by cycloheximide had no apparent influence on LPV susceptibility. The failure to detect susceptibility enhancement with three other N glycosylation processing inhibitors may point to the type of N-linked oligosaccharide involved in the susceptibility enhancement. dManNoj inhibits mannosidase I, leading preferentially to the accumulation of high-mannose structures without terminal glucose residues, whereas the other processing inhibitors used result in accumulation of either high-mannose structures with terminal glucose residues (castanospermine and dNoj) or hybrid-type oligosaccharides with terminal N-acetyl glucosamine residues (swainsonine).
Several mechanisms may be envisaged to explain the induction of LPV receptor function by interfering with cellular N glycosylation. Firstly, an N-linked oligosaccharide on the receptor protein itself might block the virus-binding site directly or indirectly by inducing a conformational change in the molecule. The masking of functional sites on cell surface molecules by oligosaccharides as a regulatory tool has been suggested (23) . One precedent for such a mechanism has recently been described. A receptor for an ecotropic murine leukemia virus is blocked in some cell lines by N glycosylation at a single specific site; removal of the site resulted in activation of receptor function (4, 27) . Secondly, the inhibitory oligosaccharide might be located on a membrane glycoprotein spatially closely associated with the receptor and thus may sterically hinder virus binding. Thirdly, the inhibitory oligosaccharide could be on a glycoprotein regulating posttranscriptional modification, transport, or degradation of the LPV receptor. Molecular identification of the LPV receptor should allow definition of which of these N glycosylation-dependent mechanisms is regulating LPV receptor expression.
